Posted in Collaborations
On June 30, 2021, the Greek pharmaceutical company Faran has proceeded to an exclusive collaboration with the biopharmaceutical company Quantum Genomics, for the development and distribution of the innovative pharmaceutical product Firibastat for the treatment of resistant hypertension and heart failure. This is a significant investment by Faran in the research and development of an innovative product. The cooperation agreement provides for the exclusive licensing and distribution of the product in the Greek market by Faran.
Firibastat is the leading product of Quantum Genomics development in the category of BAPAI (Brain Aminopeptidase A Inhibitors). It is a truly innovative triple-action therapeutic platform that forms a new path in the protection and treatment of the Cardiometabolic profile. Firibastat, targets a brain enzyme (brain APA) to treat hypertension and heart failure. The product is already in the phase 3 study stage, with encouraging early results.
Referring to the collaboration, the President & CEO of Faran, Mr. Marios Katsikas, stated: “We are particularly proud of our partnership with Quantum Genomics that marks a new era in the field of cardiology. This is a very important investment by our company in the research & development of innovative pharmaceutical products that fully expresses Faran’s business goal, to offer high-quality treatment options for the treatments of serious diseases, as well as the company’s vision to lead developments in cardiology.”
The General Manager of Faran, Mr. Panagiotis Koukoulommatis, stated: “We continue to invest in the future and set the bar high in all therapeutic categories in which we operate, working with a sense of responsibility towards patients and the Greek society. We inaugurate our collaboration with Quantum Genomics, a pioneering biopharmaceutical company in the development of a new class of drugs for the Cardiometabolic profile. The exclusive collaboration for the development and distribution of the innovative drug Firibastat in Greece, is the first of a series of Faran collaborations that will follow in the field of cardiology, in which we are dynamically entering, through a therapeutic solution that comes to fill the gap in cases of refractory hypertension and heart failure that are not covered by the existing treatment options”.
It is noted that, in Greece, 1/5 of the adult population suffers from hypertension, half of which are estimated to be undiagnosed, while 80% of patients remain unregulated.